HEALTH.2013.2.2.1-5
HEALTH.2013.2.2.1-5
8 projects · €46,662,863 total EU contribution (project-level) · 79 participating organizations · 21 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€46,662,863
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (13)
- Italy (10)
- France (9)
- UK (7)
- DK (5)
- Spain (4)
- US (4)
- AU (3)
- BE (3)
- Netherlands (3)
- SE (3)
- AT (2)
- CH (2)
- FI (2)
- HR (2)
- CZ (1)
- EE (1)
- HU (1)
- IL (1)
- IS (1)
- PL (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- KING'S COLLEGE LONDON4 projects · UK
- CERBM-GIE2 projects · FR
- HELSINGIN YLIOPISTO2 projects · FI
- AAU1 projects · DK
- AU1 projects · DK
- Leiden University Medical Center1 projects · NL
- ALU-FR1 projects · DE
- STX-Med SPRL1 projects · BE
- CHUV1 projects · CH
- CNRS1 projects · FR
- CF CONSULTING FINANZIAMENTI UNIONE EUROPEA SRL1 projects · IT
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN1 projects · DE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Multi-dimensional omics approach to stratification of patients with low back pain PAIN-OMICS · 602736 | FP7 | €5,998,886 | €8,576,694 | Details |
Natural sensory feedback for phantom limb pain modulation and therapy EPIONE · 602547 | FP7 | €5,982,840 | €8,022,135 | Details |
Mechanisms and Treatment of Migraine and its Chronification EUROHEADPAIN · 602633 | FP7 | €5,996,726 | €8,197,155 | Details |
Understanding chronic pain and new druggable targets: Focus on glial-opioid receptor interface GLORIA · 602919 | FP7 | €5,997,079 | €7,825,178 | Details |
The NGF system and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain PAINCAGE · 603191 | FP7 | €5,860,831 | €7,878,342 | Details |
Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system NEUROPAIN · 602891 | FP7 | €5,992,577 | €8,540,388 | Details |
Non-coding RNAs in neurogenic and neuropathic pain mechanisms and their application for risk assessment, patient stratification and personalised pain medicine NCRNAPAIN · 602133 | FP7 | €5,988,835 | €7,805,150 | Details |
PROBING THE ROLE OF SODIUM CHANNELS IN PAINFUL NEUROPATHIES PROPANE STUDY · 602273 | FP7 | €4,845,089 | €6,398,298 | Details |